Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Oncologists who Treat Hematologic Malignancies (US)

Articles with lock require a subscription to GLG News | Request a free trial
April 28, 2008
More potential developments in chronic lymphatic leukemia (CLL) therapy!
Analysis of: IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro | bloodjournal.hematologylibrary.org
Author: GLG Expert Contributor
ZymoGenetic appears to have a biologic that will expedite lymphocytes apoptosis (destruction) when combined with Fludara and Rituxan- 2 standard agents in this rather common & occasional refractory condition.
April 28, 2008
A Non Epo Product for Anemia of Chemotherapy? Will this dog hunt?
Analysis of: Oral PBI-1402 Demonstrates Significant Activity in Chemeotherapy-Induced Anemia Phase II Clinical Trial | www.pipelinereview.com
Author: GLG Expert Contributor
This non erythropoietin (Epo) product will raise hemoglobin levels and decrease the need for transfusions.
April 24, 2008
Advance in Small Cell Lung Cancer (SCLC)?
Analysis of: Poniard reports positive results for lung cancer drug | www.cnbc.com
Author: GLG Expert Contributor
Doubles survival BUT "comparator" arm is best supportive care. See http://investor.poniard.com/ReleaseDetail.cfm?ReleaseID=306218
April 22, 2008
Thalidomide (Celgene) use to be liberalized in Europe
Analysis of: Thalidomide Gets Boost in Europe | online.wsj.com
Author: GLG Expert Contributor
Thalidomide literally started the improved outlook in MM along with, and followed by Velcade, Revlimid and Stem Cell transplants. To now have increased access in Europe should open up that market eventhough the other agents are in widespread use (I think)
April 22, 2008
Wellpoint restricting epo products. Am I surprised?? No!!
Analysis of: WellPoint likely to follow FDA on anemia drugs | www.reuters.com
Author: GLG Expert Contributor
A major insurer (Wellpoint) is using the guidelines of the FDA to restrict erythropoietin (Epo) use.
April 21, 2008
Roche's Xeloda to gain more use in frontline treatment of m-CRC
Analysis of: Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer | jco.ascopubs.org
Author: GLG Expert Contributor
Xeloda, an oral agent, was non-inferior to infusional 5-FU, when combined ith oxaliplatin in a randomized trial in patients with metastatic colrectal cancer (m-CRC) In fact, Xeloda containing regimen was assocaited with less myelosuppression, but more rashes and diaarhea. This is good news for...
April 18, 2008
XELOX=FOLFOX! Score one for Roche!
Analysis of: Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer | jco.ascopubs.org
Author: GLG Expert Contributor
In MCRC FOLFOX which involves infusional 5FU has been the cornerstone of therapy. This study shows that an oral 5FU substitute, Xeloda, can replace the IV 5FU and expedide care and avoid cumbersome infusions.
April 15, 2008
Novartis initiated, positive in randomized phase II trial- I think they (we) may have something!
Analysis of: ASA404 begins pivotal trial to explore new approach in treating lung cancer, the leading cause of cancer death | www.pipelinereview.com
Author: GLG Expert Contributor
"ASA404 is a Tumor-Vascular Disrupting Agent (Tumor-VDA) that selectively causes the collapse of existing tumor blood supply leading to extensive tumor cell death." It is being combined with Taxol and carboplatin in a randomized phase III study.
April 15, 2008
Alimta (Lilly): Approved as First Line Agent in Europe for Non Squamous Cell Lung Ca!!!
Analysis of: ALIMTA(R) (pemetrexed for injection) Receives European Approval for Histologically-Based Use in First-Line Treatment of Most Common Lung Cancer | www.pipelinereview.com
Author: GLG Expert Contributor
Alimta will be used first line with Cis Platin as a primary therapy for non squamous non small cell lung cancer (NSCLCA)
April 14, 2008
Physician owned hospitals. Beneficial to whom? Certainly not the patient!!!
Analysis of: U.S. Reps give boost to physician-owned hospitals | www.fiercehealthcare.com
Author: GLG Expert Contributor
2 Texas U.S. Reps think that physcian owned hospitals are OK?

Previous Page : 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 Next121 to 130 of 702

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-05T01:45:24.617